By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Vermillion yesterday filed its form 10-Q with the US Securities and Exchange Commission, in which it reported first-quarter 2010 revenues of $73,000, compared to no revenues for the first quarter of 2009.

For the three months ended March 31, the company's net loss rose to $11.6 million, or $1.14 per diluted share, four times its net loss of $2.8 million, or $0.44 per share, in Q1 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.